Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Front-line Nilotinib Treatment of BCR-ABL+ Chronic Myeloid Leukaemia in Chronic Phase. An Observational Multicentre Study of the GIMEMA CML WP.

NCT01699217 is registered in ClinicalTrials.gov with Gruppo Italiano Malattie EMatologiche dell'Adulto as lead sponsor.

NCT NCT01699217
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01699217 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Front-line Nilotinib Treatment of BCR-ABL+ Chronic Myeloid Leukaemia in Chronic Phase. An Observational Multicentre Study of the GIMEMA CML WP.
Lead sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase
Observational
Overall status
Completed
Start date
June 21, 2013
Completion date
December 28, 2023
Enrollment
129 (actual)
Sites
56

Conditions

As the registry lists them; a condition with its own page is linked.

bcr-abl positive, chronic myeloid leukaemia, chronic phase philadelphia positive